Next Article in Journal
Unpacking the Mental Health of Nurses during COVID-19: Evidence from Pakistan
Next Article in Special Issue
Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience
Previous Article in Journal
Detailed Phenotype of GLA Variants Identified by the Nationwide Neurological Screening of Stroke Patients in the Czech Republic
 
 
Article

Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial

1
Division of Infectious Disease, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Korea
2
Division of Infectious Diseases, Department of Internal Medicine, Hallym University College of Medicine, Chuncheon 24252, Korea
3
Division of Infectious Diseases, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon 21565, Korea
4
Division of Infectious Diseases, Department of Internal Medicine, Inha University College of Medicine, Incheon 22332, Korea
5
Division of Infectious Diseases, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan 15255, Korea
6
Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul 07061, Korea
7
Department of Internal Medicine, Seoul Metropolitan Seobuk Hospital, Seoul 03433, Korea
*
Author to whom correspondence should be addressed.
Academic Editors: Shitij Arora and Leonidas Palaiodimos
J. Clin. Med. 2021, 10(16), 3545; https://doi.org/10.3390/jcm10163545
Received: 21 July 2021 / Revised: 11 August 2021 / Accepted: 11 August 2021 / Published: 12 August 2021
(This article belongs to the Collection COVID-19: Clinical Advances and Challenges)
Although some intravenous drugs have been used to treat coronavirus disease 2019 (COVID-19), no effective antiviral agents are currently available in the outpatient setting. We aimed to evaluate the efficacy and adverse events of 14-day ciclesonide treatment vs. standard care for patients with mild-to-moderate COVID-19. A randomized, open-label, multicenter clinical trial of ciclesonide inhalers was conducted in patients with mild-to-moderate COVID-19. Patients were enrolled within 3 days of diagnosis or within 7 days from symptom onset and randomly assigned to receive either ciclesonide (320 µg inhalation twice per day for 14 days) or standard care. The primary endpoint was the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) eradication rate on day 14 from study enrollment. Clinical status was assessed once daily, and serial nasopharyngeal viral load was evaluated by quantitative reverse transcription polymerase chain reaction. There were 35 and 26 patients in the ciclesonide and standard care groups, respectively. The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group (p = 0.021). In multivariate analysis, SARS-CoV-2 negative conversion within 14 days was 12 times more likely in the ciclesonide group (95% confidence interval, 1.187–125.240). Additionally, the clinical failure rate (high-flow nasal oxygen therapy or mechanical ventilation) was significantly lower in the ciclesonide group (p = 0.034). In conclusion, ciclesonide inhalation shortened SARS-CoV-2 viral shedding duration, and it may inhibit the progression to acute respiratory failure in patients with mild-to-moderate COVID-19. Clinical Trial Registration NCT04330586. View Full-Text
Keywords: COVID-19; SARS-CoV-2; ciclesonide; inhalation; antiviral agents COVID-19; SARS-CoV-2; ciclesonide; inhalation; antiviral agents
Show Figures

Figure 1

MDPI and ACS Style

Song, J.-Y.; Yoon, J.-G.; Seo, Y.-B.; Lee, J.; Eom, J.-S.; Lee, J.-S.; Choi, W.-S.; Lee, E.-Y.; Choi, Y.-A.; Hyun, H.-J.; Seong, H.; Noh, J.-Y.; Cheong, H.-J.; Kim, W.-J. Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial. J. Clin. Med. 2021, 10, 3545. https://doi.org/10.3390/jcm10163545

AMA Style

Song J-Y, Yoon J-G, Seo Y-B, Lee J, Eom J-S, Lee J-S, Choi W-S, Lee E-Y, Choi Y-A, Hyun H-J, Seong H, Noh J-Y, Cheong H-J, Kim W-J. Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial. Journal of Clinical Medicine. 2021; 10(16):3545. https://doi.org/10.3390/jcm10163545

Chicago/Turabian Style

Song, Joon-Young, Jin-Gu Yoon, Yu-Bin Seo, Jacob Lee, Joong-Sik Eom, Jin-Soo Lee, Won-Suk Choi, Eun-Young Lee, Young-Ah Choi, Hak-Jun Hyun, Hye Seong, Ji-Yun Noh, Hee-Jin Cheong, and Woo-Joo Kim. 2021. "Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial" Journal of Clinical Medicine 10, no. 16: 3545. https://doi.org/10.3390/jcm10163545

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop